FDA Clears Sickle Cell Drug, Casgevy, to Treat Transfusion-Dependent  Beta-Thalassemia

WEDNESDAY, Jan. 17, 2024 -- Casgevy, a groundbreaking treatment that was approved to treat sickle cell disease in December, was given the U.S. Food and Drug Administration ' s blessing on Tuesday to treat another inherited blood disorder. Casgevy is...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news